Navigation Links
Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
Date:5/28/2013

NEW YORK, May 28, 2013 /PRNewswire/ -- Omthera Pharmaceuticals and AstraZeneca announced today that the companies entered into a merger agreement under which AstraZeneca will acquire all of the outstanding stock of Omthera for an upfront payment of $12.70 in cash per share, approximately $323 million aggregate value ($260 million after subtracting cash), plus a contingent value right for up to $4.70 per share, equaling approximately $120 million and for a total value of up to $443 million. Covington & Burling LLP advised Omthera on the transaction.

Omthera is an emerging specialty pharmaceutical company led by a team of experts with exceptional experience in developing new therapies for lipid disorders. Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

The Covington team was led by corporate partner Scott Smith and corporate associate Matthew Fox, with the assistance of associates Patrick Manchester, Peter Kim and Aisha Granville.  Also advising on the transaction were partner Jim Snipes (life sciences commercial), partner Mike Lefever and associate Erik Durbin (securities), partner Seth Safra and counsel Kendra Roberson (benefits), partner Mike Labson and associates Afia Asamoah and Noellyn Davies (food & drug regulatory), partner James O'Connell and associate James Burke (antitrust), and partner Rob Heller and associate Sarah Burnham (tax).

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Seoul, Shanghai, Silicon Valley, and Washington, DC.

Contact: An Pham
+1.202.662.6575
apham@cov.com


'/>"/>
SOURCE Covington & Burling LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
2. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
3. Underage Kids Get Hydrocodone Drugs Easily from Family & Friends, Advises New York Center for Living
4. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
5. Apex BioStrategists Advises On Flow Cytometry Sale To Coulter
6. Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc
7. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
8. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology:
(Date:9/26/2017)... MA (PRWEB) , ... September 26, 2017 , ... CGL ... its first office under its new umbrella, CGL Technologies, LLC. , The new CGL ... industry veterans Remo Patitucci and Jon McCormack, both of whom have creative business development ...
(Date:9/26/2017)... ... 26, 2017 , ... As the holiday season nears, best deals online ... constantly trying to find tips and stories for products and services savings. With a ... top trending deals. The deals are organized by categories so can easily find what ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... Device Manufacturers, **An FDAnews Management Report**, http://www.fdanews.com/products/54648-principles-of-equipment-qualification      , ... Manufacturers must prove that their equipment, operations and processes all work the ...
(Date:9/26/2017)... (PRWEB) , ... September 26, 2017 , ... Founded as ... decades growing into an innovative leader in special education. In 2018, Glenholme will ... , Glenholme, formerly a world renowned horse farm for Hackney show ponies, was generously ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... services in Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, will ... (ABA) services. Aspire provides center based Autism services in Broomfield and will continue ...
Breaking Medicine News(10 mins):